Vitestro raises 12m in Series A financing
With assets of 12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
With assets of 12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a 15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
The fourth fund of High-Tech Gründerfonds has reached a final fund volume of 493.8m
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
Interferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.
French Abivax SA has raised 130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
PVH Corp has joined fiber-to-fiber consortium that wants to make textile recycling sustainable by establishing standards for biorecycled textile fibre.